

Rule 15c2-11 (a)(5) Information under the Securities Exchange Act of 1934

- i. the exact name of the issuer and its predecessor (if any):

Deltagen, Inc.

- ii. the address of its principal executive offices:

1900 S. Norfolk St., Suite 105, San Mateo, CA 94403

- iii. the state of incorporation, if it is a corporation:

Delaware

- iv. the exact title and class of the security:

Common Stock

- v. the par or stated value of the security:

\$0.001

- vi. the number of shares or total amount of the securities outstanding as of the end of the issuer's most recent fiscal year:

as of 12/31/08 42,588,398; after 12/10/2009: 51,714,484

- vii. the name and address of the transfer agent:

Computershare, 350 Indiana Street, Suite 750, Golden CO 80401

- viii. the nature of the issuer's business:

Deltagen is a leading provider of drug discovery tools and services to the biopharmaceutical industry.

- ix. the nature of products or services offered:

Deltagen offers a suite of programs designed to enhance the efficiency of drug discovery, including access to biological models. In addition, Deltagen offers target validation data in the areas of immunology and metabolic diseases.

- x. the nature and extent of the issuer's facilities:

Offices in San Mateo, California and Lancaster, Pennsylvania

- xi. the name of the chief executive officer and members of the board of directors:

Robert J. Driscoll, CEO and Director
Constantine E. Anagnostopoulos, Chairman and Director
William A. Scott, Director
Marty J. Herson, Director
Thomas A. Penn, Director

- xii. the issuer's most recent balance sheet and profit and loss and retained earnings statements:

Click HERE (<http://www.deltagen.com/pressreleases/20091210pressrelease.pdf>) to go to the information.

- xiii. similar financial information for such part of the 2 preceding fiscal years as the issuer or its predecessor has been in existence:

Click HERE (<http://www.deltagen.com/pressreleases/pressreleases.html>) to go to the information.